Advances in Lung Cancer Treatment

Thursday, January 4, 2024, 8:00 AM - Sunday, January 3, 2027, 8:00 AM

 

Advances in Lung Cancer Treatment is an organized review of Advanced Pre and Post-Operative Treatment for Recurrence Prevention and Extending Disease-Free Survival.

Here's what you can expect to learn from this course:

• A comprehensive understanding of the latest pre and post-operative treatments for lung cancer recurrence prevention and disease-free survival extension.
• An in-depth discussion of the role of immunotherapy and targeted therapy in the context of lung cancer treatment.
• The latest research and advancements in lung cancer treatment, and how they impact patient care.
• Brief review of previous types of treatments
• Detailed discussion of individual molecular targets for treatment and the different drugs available to treat each of these targets
• Detailed discussion of the interaction of the immune system with cancer cells and drugs used to alter these interactions for the treatment of lung cancer
• Importance of Biomarker Testing and Further Clinical Investigations
  Future directions for research
  
  By the end of this course, you'll have gained valuable insights into the most advanced pre and post-operative treatments for lung cancer recurrence prevention and disease-free survival extension. You'll also have a solid understanding of the latest research and advancements in lung cancer treatment, and how to apply them to optimize patient outcomes.

AMA PRA Category 1 Credits™ (3.00 hours), Non-Physician Attendance (3.00 hours)

1. Demonstrate knowledge of outcomes with conventional treatment of non small cell lung cancer.
2. Demonstrate knowledge of improved outcomes than can be obtained with advanced treatment modalities for non small cell lung cancer and date from clinical trials
3. Demonstrate knowledge of the importance of biomarker testing in patients with non small cell lung cancer.
4. Demonstrate knowledge of future directions of research & investigation in the treatment of non small cell lung cancer.

ACCME Accreditation: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Quillen College of Medicine, East Tennessee State University and Dr. D. Tyler Greenfield. The Quillen College of Medicine, East Tennessee State University is accredited by the ACCME to provide continuing medical education for physicians. 

 

CME Credit: Quillen College of Medicine, East Tennessee State University, designates this activity for a maximum of 3.00 AMA PRA Category 1 Credits^TM . Physicians should only claim credit commensurate with the extent of their participation in the activity.

Accessibility Statement
 
East Tennessee State University Quillen College of Medicine Department of Continuing Education for Health Professionals is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008.  If you have needs that require special accommodations, including dietary concerns, please contact the CME Conference Coordinator.

You are not logged in.

Please click the button below to login or create a new account before continuing.

The East Tennessee State Quillen College of Medicine Department of Continuing Education for Health Professionals adheres to ACCME Criteria, Standards and Policies regarding industry support of continuing medical education. Disclosure of faculty and their commercial relationships will be made prior to the activity.

Mitigation of Relevant Financial Relationships

East Tennessee State University Continuing Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.